ATE170220T1 - Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten - Google Patents

Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten

Info

Publication number
ATE170220T1
ATE170220T1 AT92900527T AT92900527T ATE170220T1 AT E170220 T1 ATE170220 T1 AT E170220T1 AT 92900527 T AT92900527 T AT 92900527T AT 92900527 T AT92900527 T AT 92900527T AT E170220 T1 ATE170220 T1 AT E170220T1
Authority
AT
Austria
Prior art keywords
therapeutic agent
chronic viral
liver disease
agent against
against chronic
Prior art date
Application number
AT92900527T
Other languages
English (en)
Inventor
Hans A Thoma
Original Assignee
Medeva Holdings Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8204863&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE170220(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medeva Holdings Bv filed Critical Medeva Holdings Bv
Application granted granted Critical
Publication of ATE170220T1 publication Critical patent/ATE170220T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT92900527T 1990-12-19 1991-12-19 Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten ATE170220T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90124775A EP0491077A1 (de) 1990-12-19 1990-12-19 Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten

Publications (1)

Publication Number Publication Date
ATE170220T1 true ATE170220T1 (de) 1998-09-15

Family

ID=8204863

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92900527T ATE170220T1 (de) 1990-12-19 1991-12-19 Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten

Country Status (15)

Country Link
US (2) US6020167A (de)
EP (2) EP0491077A1 (de)
JP (2) JP3857305B2 (de)
KR (1) KR0156587B1 (de)
AT (1) ATE170220T1 (de)
AU (1) AU657935B2 (de)
CA (1) CA2098021C (de)
CZ (1) CZ290233B6 (de)
DE (1) DE69130071T3 (de)
DK (1) DK0563093T4 (de)
ES (1) ES2121000T5 (de)
HK (1) HK1002901A1 (de)
HU (1) HU216301B (de)
SK (1) SK280551B6 (de)
WO (1) WO1992011368A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2758184B2 (ja) * 1987-06-22 1998-05-28 メデバ ホールディングス ベスローテン ベノートスハップ 肝炎ｂ表面抗原ワクチン
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
DE4107612A1 (de) 1991-03-09 1992-09-10 Behringwerke Ag Rekombinante proteine mit der immunreaktivitaet des hepatitis b virus e antigens (hbeag), verfahren zu ihrer herstellung und ihre verwendung in immunoassays und impfstoffen
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US6509149B2 (en) 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides
EP0912195B1 (de) * 1996-06-25 2009-01-21 Pepscan Systems B.V. Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
KR20080059679A (ko) 2000-03-29 2008-06-30 조지타운 유니버시티 델타형 간염 바이러스 감염의 치료방법
IL142802A (en) * 2000-04-27 2015-01-29 Enzo Therapeutics Inc Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
EP1357940A4 (de) * 2001-02-05 2004-03-17 Stressgen Biotechnologies Corp Hepatitis?b?virustherapie
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
AU2003210060B2 (en) * 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
DE10339927A1 (de) * 2003-08-29 2005-03-24 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
EP1682894B1 (de) * 2003-11-12 2011-01-05 HBV Theranostica AB Verfahren in verbindung mit einer hepatitis-b-infektion
GB0326416D0 (en) 2003-11-12 2003-12-17 Karolinska Innovations Ab Methods and means relating to hepatitis B infection
US9603921B2 (en) * 2004-10-27 2017-03-28 Janssen Vaccines Ag Virosome particles comprising antigens from influenza virus and hepatitis b virus
WO2009022236A2 (en) * 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
WO2009092396A1 (en) 2008-01-25 2009-07-30 Universitätsklinikum Heidelberg Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors
CN101485672B (zh) * 2008-12-05 2010-08-25 广东粤龙药业有限公司 异丙景糖酐在制备治疗人HBeAg阳性慢性乙型肝炎药物中的应用
CN102573903B (zh) 2009-08-07 2015-12-02 特兰斯吉恩股份有限公司 用于治疗hbv感染的组合物
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34705A (en) * 1862-03-18 Improvement in tompions for fire-arms
US3636191A (en) * 1969-10-08 1972-01-18 Cancer Res Inst Vaccine against viral hepatitis and process
FR2480779B2 (fr) * 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
NZ192465A (en) * 1978-12-22 1983-09-30 Biogen Nv Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof
EP0182442B2 (de) * 1978-12-22 1996-04-03 Biogen, Inc. Rekombinante DNS-Moleküle und Verfahren zur Herstellung derselben
US4935235A (en) * 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
US5196194A (en) * 1979-05-24 1993-03-23 The Regents Of The University Of California Vaccines containing Hepatitis B S-protein
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
USRE34705E (en) 1979-08-30 1994-08-23 Institut Pasteur Nucleotidic sequence coding the surface antigen of the hepatitis B virus, vector containing said nucleotidic sequence, process allowing the obtention thereof and antigen obtained thereby
US4415491A (en) * 1980-01-14 1983-11-15 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
DE3176404D1 (en) * 1980-04-22 1987-10-08 Pasteur Institut Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
IL63224A (en) * 1980-07-17 1985-05-31 Scripps Clinic Res Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom
GR76274B (de) * 1981-08-04 1984-08-04 Univ California
AU8746582A (en) * 1981-09-02 1983-03-10 Biogen N.V. Hepatitis b virus e type antigen
US4741901A (en) * 1981-12-03 1988-05-03 Genentech, Inc. Preparation of polypeptides in vertebrate cell culture
JPS58194897A (ja) * 1982-05-07 1983-11-12 Takeda Chem Ind Ltd 新規ｄｎａ，その製造方法およびそれで形質転換させた宿主
JPS5936698A (ja) * 1982-08-20 1984-02-28 Science & Tech Agency Ｂ型肝炎ウイルス遺伝子を組込んだ組換えｄｎａおよび形質転換動物細胞
US4977092A (en) * 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US5198348A (en) * 1982-08-30 1993-03-30 Amgen Inc. Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
JPS5974985A (ja) * 1982-10-19 1984-04-27 Takeda Chem Ind Ltd 新規ｄｎａ
CA1341116C (en) * 1983-02-22 2000-10-17 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein
US4696898A (en) * 1984-01-16 1987-09-29 Integrated Genetics, Inc. Vector encoding hepatitis B surface antigen
FR2559159B1 (fr) * 1984-02-02 1986-09-12 Inst Nat Sante Rech Med Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues
US5324513A (en) * 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
US5158769A (en) * 1984-03-07 1992-10-27 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4861588A (en) * 1985-02-05 1989-08-29 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US5204096A (en) * 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4847080A (en) * 1984-03-07 1989-07-11 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
FR2560890B1 (fr) * 1984-03-07 1987-10-16 Grp Genie Genetique Composition utile pour la fabrication de vaccins contenant des particules portant l'antigene de surface du virus de l'hepatite b et le recepteur de l'albumine serique humaine polymerisee, cellules animales capables de produire de telles particules et procede pour leur obtention
US4942125A (en) * 1984-09-07 1990-07-17 Scripps Clinic And Research Foundation SV40 expression vector containing HBxAg as an expression marker
US4777240A (en) * 1984-03-08 1988-10-11 Scripps Clinic And Research Foundation SV40 expression vector containing HBxAg as an expression marker
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
AU579148B2 (en) * 1984-03-09 1988-11-17 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell and b cell determinants
US5098704A (en) * 1984-06-18 1992-03-24 Chiron Corporation Hepatitis surface antigen particle vaccine
EP0171908A3 (de) * 1984-07-11 1987-07-15 Takeda Chemical Industries, Ltd. Hepatitis-B-Virus-Oberflächenantigen und dessen Herstellung
GB8421282D0 (en) * 1984-08-22 1984-09-26 Connaught Lab Multispecific antigenic proteins
US4722940A (en) * 1984-08-23 1988-02-02 Georgia Tech Research Corporation Aminoalkyl phenyl selenides for the treatment of hypertension and nervous system dysfunctions
EP0175261B1 (de) * 1984-09-12 1991-12-11 Chiron Corporation Hybridpartikel-Immunogene
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4639371A (en) * 1984-10-02 1987-01-27 New York Blood Center, Inc. Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom
EP0180012A1 (de) * 1984-10-27 1986-05-07 Wolfram H. Prof. Dr. Gerlich Immunogene Polypeptidsequenz des Hepatitis B-Virus
US4683136A (en) * 1985-03-06 1987-07-28 Scripps Clinic And Research Foundation Proteinaceous antigens with conformation-independent and conformation-dependent determinants
CA1324094C (en) * 1985-04-03 1993-11-09 Dino Dina Hepatitis a virus vaccines
FI861417A0 (fi) * 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US5837249A (en) * 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4639271A (en) * 1985-04-24 1987-01-27 Moore Business Forms, Inc. Chromogenic mixtures
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
JPH084507B2 (ja) * 1985-10-03 1996-01-24 武田薬品工業株式会社 新規ｄｎａおよびポリペプチド
US4959323A (en) * 1985-11-04 1990-09-25 Mt. Sinai School Of Medicine Of The City University Of New York Production and use of pre S polypeptides of hepatitis B virus
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
US4742158A (en) * 1986-04-25 1988-05-03 Merck & Co., Inc. Purification of hepatitis pre-S antigens by polymerized serum albumin affinity binding
IE59389B1 (en) * 1986-05-23 1994-12-23 Merck & Co Inc Method for producing hepatitis b virus core antigen (HBcAg) in yeast
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein
WO1987007896A1 (en) * 1986-06-20 1987-12-30 Scripps Clinic And Research Foundation T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
US5068185A (en) * 1986-07-10 1991-11-26 Merck & Co., Inc. Trains of yeast for the expression of heterologous genes
IL79740A0 (en) * 1986-08-17 1986-11-30 Yeda Res & Dev Hepatitis vaccine
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
AP56A (en) * 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
EP1088830A3 (de) * 1987-06-22 2004-04-07 Medeva Holdings B.V. Partikel von Hepatitis B Oberflächenantigen
JP2758184B2 (ja) * 1987-06-22 1998-05-28 メデバ ホールディングス ベスローテン ベノートスハップ 肝炎ｂ表面抗原ワクチン
US4883865A (en) * 1987-09-30 1989-11-28 Merck & Co. Inc. Recovery of pres2+s antigen
US4963483A (en) * 1987-10-13 1990-10-16 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
US5039522A (en) * 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
NZ229260A (en) * 1988-06-03 1994-02-25 Merck & Co Inc Hepatitis b virus, expression cassette for pre-s domain, host cells and
US5242812A (en) * 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
US5462863A (en) * 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
GB8903313D0 (en) * 1989-02-14 1989-04-05 Wellcome Found Conjugates
SG48175A1 (en) * 1989-07-25 1998-04-17 Smithkline Beecham Biolog Novel antigens and method for their preparation
CA2025481A1 (en) * 1989-09-19 1991-03-20 Peter J. Kniskern Vaccine for aids and hepatitis b
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
US5102989A (en) * 1991-03-15 1992-04-07 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
IL101653A0 (en) * 1991-04-29 1992-12-30 Merck & Co Inc Multiple hepatitis b virus surface proteins which form particles
CA2067003A1 (en) * 1991-04-29 1992-10-30 Peter J. Kniskern Hbsag escape mutant vaccine
US5840303A (en) * 1991-08-26 1998-11-24 The Scripps Research Foundation Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
JP2501186Y2 (ja) * 1992-03-31 1996-06-12 株式会社栗本鐵工所 ハンマ―ミル
CN1063343C (zh) * 1993-04-27 2001-03-21 中国科学院上海生物化学研究所 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
CN1094311A (zh) * 1993-04-27 1994-11-02 中国科学院上海生物化学研究所 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
CN1059927C (zh) * 1994-03-10 2000-12-27 中国科学院上海生物化学研究所 羧端带有前表面抗原1抗原决定簇的乙肝表面抗原融合基因及其编码蛋白
US5792163A (en) * 1996-01-03 1998-08-11 Hitzig; Gary Linear punch

Also Published As

Publication number Publication date
JPH06507303A (ja) 1994-08-25
US6020167A (en) 2000-02-01
EP0563093B1 (de) 1998-08-26
EP0563093A1 (de) 1993-10-06
HK1002901A1 (en) 1998-09-25
EP0491077A1 (de) 1992-06-24
US20030235591A1 (en) 2003-12-25
HUT66437A (en) 1994-11-28
AU657935B2 (en) 1995-03-30
WO1992011368A1 (en) 1992-07-09
KR0156587B1 (en) 1998-10-15
JP2001019643A (ja) 2001-01-23
AU9081791A (en) 1992-07-22
CA2098021C (en) 2000-04-25
DE69130071D1 (de) 1998-10-01
DK0563093T4 (da) 2008-01-21
ES2121000T3 (es) 1998-11-16
DE69130071T2 (de) 1999-01-07
ES2121000T5 (es) 2008-04-16
SK280551B6 (sk) 2000-03-13
JP3857305B2 (ja) 2006-12-13
HU9301794D0 (en) 1993-10-28
SK63693A3 (en) 1993-10-06
CA2098021A1 (en) 1992-06-20
DK0563093T3 (da) 1999-02-08
EP0563093B2 (de) 2007-10-03
CZ118693A3 (en) 1994-02-16
HU216301B (hu) 1999-06-28
DE69130071T3 (de) 2008-02-21
CZ290233B6 (cs) 2002-06-12

Similar Documents

Publication Publication Date Title
ATE170220T1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
PT725824E (pt) Epitopos de celulas t humanas imunodominantes do virus da hepatite c
DK486588D0 (da) Konjungater af cytokininer med immunglobuliner
NO893894D0 (no) Non-a, nok-b hepatittvirus antigen-peptid.
DE69738351D1 (de) Verfaheren zur durch rekombinante adeno-assoziierte virus-gerichtete gentherapie
ATE141946T1 (de) Hiv-2-virusvarianten
ATE265535T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
FI923347A (fi) Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
ATE334590T1 (de) Anti-arrhythmische zusammensetzungen und behandlungsverfahren
KR910007531A (ko) 15-케토-프로스타글란딘 화합물을 이용한 간 담즙성 질병의 치료
KR910009270A (ko) 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법
ATE58478T1 (de) Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
DE68927340D1 (de) Biologischer impfstoff, wirksam gegen aphanomyces
ATE64855T1 (de) Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
ATE144103T1 (de) Biologischer impfstoff, wirksam gegen aphanomyces
MXPA94003453A (es) Metodo y composicion para el tratamiento de pacientes con hepatitis b que tienen descompensacion hepatica.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0563093

Country of ref document: EP

REN Ceased due to non-payment of the annual fee